rozanolixizumab

About UCB Pharma

UCB Pharma is a patient-centric, global biopharmaceutical company with a strategic focus on severe neurological and autoimmune diseases. Leveraging deep expertise in antibody engineering, biologics, and small molecules, it has built a sustainable innovation engine and a commercial portfolio anchored by blockbusters like Cimzia and Vimpat. The company's strategy is centered on expanding its core immunology franchise with bimekizumab, pioneering novel mechanisms like FcRn inhibition in neurology, and advancing a maturing late-stage pipeline to drive its next wave of growth.

About UCB Pharma

UCB Pharma is a patient-centric, global biopharmaceutical company with a strategic focus on severe neurological and autoimmune diseases. Leveraging deep expertise in antibody engineering, biologics, and small molecules, it has built a sustainable innovation engine and a commercial portfolio anchored by blockbusters like Cimzia and Vimpat. The company's strategy is centered on expanding its core immunology franchise with bimekizumab, pioneering novel mechanisms like FcRn inhibition in neurology, and advancing a maturing late-stage pipeline to drive its next wave of growth.

About Astellas Pharma

Astellas Pharma is a Japan-based global pharmaceutical leader with a mission to deliver transformative therapies in areas of high unmet medical need. Formed by the 2005 merger of Yamanouchi and Fujisawa, the company has grown into a $45.8 billion market cap entity with a vertically integrated model spanning R&D, manufacturing, and global commercialization. Its strategy is anchored in a patient-centric approach, a robust pipeline, and strategic external innovation to drive growth in core therapeutic areas and next-generation modalities.

About UCB

UCB is a mission-driven, global biopharmaceutical company dedicated to improving the lives of patients with severe diseases in neurology and immunology. The company has achieved a successful strategic transformation, now boasting a market capitalization of approximately $48.3 billion, a commercial portfolio including key products like bimekizumab, and a deep, late-stage pipeline of 609 candidates. Its strategy is anchored in patient-inspired science, a sophisticated technology platform for antibody and biomarker discovery, and a commitment to sustainable growth through internal R&D and strategic external innovation.

About UCB

UCB is a mission-driven, global biopharmaceutical company dedicated to improving the lives of patients with severe diseases in neurology and immunology. The company has achieved a successful strategic transformation, now boasting a market capitalization of approximately $48.3 billion, a commercial portfolio including key products like bimekizumab, and a deep, late-stage pipeline of 609 candidates. Its strategy is anchored in patient-inspired science, a sophisticated technology platform for antibody and biomarker discovery, and a commitment to sustainable growth through internal R&D and strategic external innovation.

Therapeutic Areas